Actionable news
0
All posts from Actionable news
Actionable news in CTSO: CYTOSORBENTS Corp,

CytoSorbents to Report Q3 2016 Operating and Financial Results

MONMOUTH JUNCTION, N.J., Nov. 1, 2016 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® extracorporeal cytokine adsorber to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q3 2016 financial results after the market close on Monday, November 7, 2016.

CytoSorbents' management will host a live conference call and presentation webcast that will recount both operational and financial progress during Q3 2016 followed by a question and answer session.

Conference Call Details:
Date: Monday, November 7, 2016
Time: 4:45 PM Eastern
Participant Dial-In: 1-719-457-2605
Live Presentation Webcast: http://public.viavid.com/index.php?id=121492

It is recommended that participants dial in approximately 10 minutes prior to the start of the call. There will also be a simultaneous live webcast of the conference call that can be accessed through the following audio feed link: http://public.viavid.com/index.php?id=121492

An archived recording of the conference call will be available under the Investor Relations section of the Company's website at http://cytosorbents.com/investor-relations/financial-results/.

About CytoSorbents Corporation
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 40 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine...


More